pISSN 1226-6051
eISSN 2508-786X

Table. 3.

Table. 3.

Efficacy and safety of once weekly oral semaglutide compared to placebo for weight loss in overweight or obese adults without type 2 diabetes36)

Trial Trial duration Study drugs Mean body weight change from baseline (ETD, 95% CI, p-value) Proportion achieving body weight reduction of ≥5%, % (OR, 95% CI, p-value) Proportion achieving body weight reduction of ≥10%, % (OR, 95% CI, p-value) Proportion achieving body weight reduction of ≥15%, % (OR, 95% CI, p-value) Proportion achieving body weight reduction of ≥20%, % (OR, 95% CI, p-value) GI adverse events (%) GI adverse events leading to premature treatment discontinuation (%)
OASIS 1 68 weeks Semaglutide 50 mg (n=334) -15.1% (-12.7, -14.2 to -11.3, p<0.0001) (n=317) 85 (12.6, 8.5 to 18.7, p<0.0001) 69 (14.7, 9.6 to 22.6, p<0.0001) 54 (17.9, 10.4 to 30.7, p<0.0001) 34 (18.5, 8.8 to 38.9, p<0.0001) 80 4
Placebo, reference (n=333) -2.4% (n=295) 26 12 6 3 46 2

CI: confidence interval; ETD: estimated treatment difference; GI: gastrointestinal; OR: odds ratio

Korean J Clin Pharm 2024;34:1-20 https://doi.org/10.24304/kjcp.2024.34.1.1
© 2024 Korean J Clin Pharm